Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
A combination therapy pairing Takeda Pharmaceutical’s tyrosine kinase inhibitor Cabometyx (cabozantinib) and Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) reduced the risk of disease progression or death by 35% in certain prostate cancer patients, according to the latest data update. The…
To read the full story
Related Article
- Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
August 23, 2023
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
BUSINESS
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…